QUE Oncology is a clinical stage company focussed on developing Q-122 for the treatment of hot flashes in cancer survivors undergoing endocrine therapy.
The incidence of hormone-responsive cancers, such as breast and prostate cancer are increasing. Nonetheless, the development of new treatments, including endocrine therapies, have improved survival and remission rates in these patients.
While endocrine therapies are efficacious, a significant proportion of patients experience severe hot flashes during therapy – a well-recognised side effect. All approved treatments for hot flashes are contraindicated for these patients, leaving them with no available options to manage this side effect. The severity of hot flashes in these patients have resulted in many being non-compliant with treatment, or in some cases – ceasing life-saving therapy altogether. This represents an area of unmet medical need.
QUE Oncology’s lead program, Q-122 is an orally bioavailable small molecule has previously demonstrated an excellent safety profile and is currently undergoing phase 2 trials.. The phase 2 trials are conducted across 10 hospitals in the US and Australia, focussing on breast cancer survivors with endocrine therapy induced hot flashes. Results from this trial will be available in 2020.
It is anticipated that a successful outcome may position this treatment for the broader indication of hot flashes in menopausal women.